Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors. Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer
Faculty review recent clinical trial data and provide their insights on the use of CDK4/6 inhibitors and PI3K inhibitors for HR+/HER2- breast cancer.
Hear expert perspective from Laura M. Spring, MD, on how she will integrate adjuvant abemaciclib into clinical practice.